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Rodrigo Calado, Zachary C. G. Tucker, Peiman Hematti, Jaroslaw Maciejewski,
Cynthia Dunbar, John Barrett, Neal YoungGraft-versus-host disease (GVHD) is a major risk factor for secondary malignancy after hematopoietic stem
cell transplantation. Squamous cell carcinoma (SCC) of the skin and mucous membranes are especially fre-
quent in this setting where aneuploidy and tetraploidy are associated with aggressive disease. The current
study is directed at the mechanism of neoplasia in this setting. Unmanipulated keratinocytes from areas of
oral GVHD in 9 patients showed tetraploidy in 10% to 46% of cells when examined by florescein in situ hy-
bridization (FISH). Keratinocytes isolated from biopsy sites of GVHD but not from normal tissue showed
even greater numbers of tetraploid cells (mean 5 78%, range: 15%-85%; N 5 9) after culture. To mimic
the inflammatory process in GVHD, allogeneic HLA-mismatched lymphocytes were mixed with normal ker-
atinocytes. After 2 weeks, substantial numbers of aneuploid and tetraploid cells were evident in cultures with
lymphocytes and with purified CD8 but not CD4 cells. Telomere length was substantially decreased in the
lymphocyte-treated sample. No mutations were present in the p53 gene, although haploinsufficiency for p53
due to the loss of chromosome 17 was common in cells exposed to lymphocytes. These findings suggest that
in GVHD, inflammation and repeated cell division correlate with the development of karyotypic
abnormalities.
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TetraploidyINTRODUCTION
Recipients of solid organ and bone marrow trans-
plants (BMTs) are at risk of developing solid tumors.
Two percent to 6% of long-term survivors acquire
some type of malignancy by 10 years of follow-up
[1-4]. Although radiation therapy increases the risk
of nonsquamous cell carcinomas of breast, brain, and
bone, and of melanoma [5,6], chronic graft-versus-
host disease (cGVHD) and its therapy increase the
probability of developing squamous cell carcinomaNational Heart, Lung, and Blood Institute, Bethesda,
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6/j.bbmt.2010.07.014(SCC) of the skin and oral cavity [7]. In one study,
the risk for SCC among transplant recipients with
cGVHD was 3-fold that of patients without GVHD
[7]. Major risk factors included a long duration of
cGVHD therapy, use of azathioprine, and severity
of cGVHD; the conditioning regimen or the use of
high-dose radiation did not influence the incidence
of SCC. In BMT patients, the relative contributions
of immunosuppression and the inflammatory effects
of cGVHD cannot be ascertained. However, in pa-
tients receiving solid organ transplants, immunosup-
pression alone has been associated with SCC, and
a randomized trial of immunosuppression reduction
showed significantly fewer cancers in those receiving
the less intense regimen [8,9].
Chronic inflammation alone is associated with in-
creased risk of cancer in some conditions. Examples
include bowel cancer in ulcerative colitis [10], esopha-
geal cancer in Barrett’s esophagitis [11], and hepatoma
in hepatitis B [12]. DNA damage in areas of inflamma-
tion is believed to be related to reactive oxygen species
[13-15], and in vitro exposure to endogenous oxidants1665
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Polypoid and aneuploid cells are evident at sites of
inflammation preceding the development of cancer in
Barrett’s esophagus [17], in hepatocytes after partial
hepatectomy [18], in ulcerative colitis [10], and tran-
siently in skin wounds and burns [19]. Mutation or
loss of a pivotal oncogene, TP53 [20], also occurs in
areas of inflammation [21]. TP53 is a checkpoint gene
that forces cells with substantial DNA damage into
senescence or apoptosis [22,23]. Approximately 85%
of colon cancers resulting from inflammatory bowel
disease have lost at least 1 TP53 allele [21]. Haplo-
insufficiency, gene duplication, or mutation of TP53
allows cells with polyploidy to continue to live and
divide [24]. It has been theorized that in inflammatory
disorders, repeated oxidative stress results in TP53
mutation or loss [21]. An alternative mechanism for
the development of ploidy involves telomeric shorten-
ing resulting from repeated cell division accompanying
tissue repair [25]. In the telomerase-deficient mouse,
significant telomeric shortening results in end-to-end
fusion of chromatids with consequent nondisjunction
during metaphase and aneuploidy [26].
Tetraploidy and aneuploidy are present in most
cases of SCC and complex chromosomal abnormalities
correlate with poor prognosis [27-29]. Tetraploidy
results from chromosome nondisjunction in late
mitosis SCC [28,30-34] and precedes the development
of aneuploidy in some models [26]. In this study, we
examined sites of oral and skin GVHD in transplant
patients and developed an in vitro model of GVHD us-
ing keratinocytes cocultured with HLA mismatched
allogeneic lymphocytes or inflammatory cytokines.
We also assessed the effect of inflammation on telomere
length andTP53 in an effort to develop amechanism for
the occurrence of SCC in patients with GVHD.MATERIALS AND METHODS
Patients
Patients undergoing hematopoietic stem cell
transplantation (HSCT) were recruited for the study
using a protocol approved by the institutional review
board of the National Heart, Lung, and Blood Insti-
tute, after written informed consent. All patients
were adults with a hematologic disorders who had
received a granulocyte colony-stimulating factor (G-
CSF)-mobilized peripheral blood allograft from a fully
HLA-matched male sibling donor. Some patients re-
ceived full myeloablation with total body irradiation
(TBI) (1360 rad) and cyclophosphamide (Cy) 60 mg/
kg/day for 2 days, followed by infusion of grafts that
were T cell depleted by positive selection for CD341
cells via the Isolex immunoabsorption device. Other
patients received nonmanipulated G-CSF mobilized
peripheral blood cells following a nonmyeloablativeconditioning regimen of fludarabine and Cy. Samples
were obtained from patients who were transplanted
a minimum of 2 months before the biopsy and were
confirmed to have full donor engraftment by BM cyto-
genetics or by polymerase chain reaction (PCR)-based
microsatellite chimerism analysis of the peripheral
blood. Patients were required to have either active
biopsy-proven cutaneous GVHD at the time of skin
biopsy or oral buccal mucosal smear. Patients with
oral GVHD were diagnosed on clinical grounds.Cell Preparation and Tissue Culture
Buccal mucosal cells
Buccal mucosal cells were obtained by scraping the
area of the oral mucosa that appeared to be most in-
volved with GVHD. Cells were placed directly on
the slide, after which they were fixed and prepared
for FISH. Generally, several mucosal scrapings were
obtained from the patient so that many cells could be
examined. Buccal mucosal cells were also obtained
from 10 healthy volunteers.
Skin biopsies from GVHD patients
Two contiguous 4 to 6 mm punch biopsy samples
from a site of ongoing or previous cutaneous GVHD
were obtained from each patient with significant
GVHD by standard techniques [35]. One specimen
was fixed in formalin and embedded in paraffin for rou-
tine histologic evaluation. The second specimen was
treated at 4Covernightwith dispase (Becton-Dickinson
Labware, Bedford, MA, USA), a type IV collagenase, to
separate the epidermal layer from the basement
membrane. The epidermal sheet was then separated
mechanically from the dermal layer and cells were disso-
ciated by shaking and digesting with 0.5% trypsin-0.53
mM EDTA (Gibco BRL, Gaithersburg, MD, USA) at
37C. The cells were plated on tissue culture dishes in
keratinocytes-serum-free media (Gibco BRL) supple-
mented with bovine pituitary extract and recombinant
epidermal growth factor. Cells were expanded to larger
flasks using trypsinization when themonolayers reached
60% to 70% confluence.
Culture of keratinocytes obtained from foreskins
To study normal keratinocytes, we obtained thoses
isolated from foreskin fibroblasts fromCarole Yee et al.
(isolation detailed elsewhere) [35] and cultured as previ-
ously described in keratinocyte growth media [35]. To
assess the effect of inflammation, one flask of confluent
keratinocytes was cocultured with normal peripheral
blood mononuclear cells with or without interferon-
gamma (IFN-g) (1000 units/mL), or in some cases
with isolatedCD4orCD8 cells.Nonadherent lympho-
cytes were removed after 48 hours at 37C, and fresh
media was added to the keratinocytes. Keratinocytes
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saged two times before preparation for florescence in
situ hybridization (FISH).
FISH
Keratinocytes were exposed to trypsin, enumer-
ated, and fixed to glass slides. Cells were incubated in
prewarmed hypotonic solution (0.3% KCl sol) at
37C for 30 minutes, spun, and resuspended in Car-
noy’s fixative (3 parts methanol and 1 part glacial acetic
acid) three times. Fixed cells were dropped onto
cleaned glass slides and dried overnight. Before hy-
bridization, slides were incubated in 2SSC for 2 min-
utes at 73C, then digested with pepsin for 5minutes at
37C and dehydrated in serial ethanol washes. CEP
combined X/Y (spectrum orange and spectrum green,
respectively) centromeric probe (Vysis, Inc, Downers
Grove, IL, USA) was used for markers of tetraploidy
because it is capable of distinguishing fusion cells
from cells that are tetraploid secondary to failure of
cytokinesis. Three hundred cells were scored by three
‘‘blinded’’ observers on all samples except for the buc-
cal smears, in which all available cells were counted.
Cells were scored according to current guidelines
[36]; cells containing twice the normal complement
of stained chromosomes were defined as tetraploid;
other abnormal gains or losses were defined as aneu-
ploid.
Centromeric probes for chromosomes 7, 8, and 9
(Abbott Laboratories, Abbott Park, IL, USA) were used
for experiments with normal keratinocytes. Locus-
specific p53 probe (Abbott) was used to assess loss of het-
erozygosity in keratinocytes. Slides were placed on the
Hybrite hybridization system (Abbott), and the samples
were denatured at 73C for 2 minutes. After overnight
hybridization at 42C, the slides were washed in pre-
warmed 0.4SSC at 73C for 2 minutes and 2SSC/
0.1% NP-40 at room temperature for 1 minute. The
slides were dried in the dark, and then counterstained
withDAPI-Ibeforeexaminationusingafluorescencemi-
croscope. The overnight hybridization temperature for
the TP53 locus specific probe was 37C.
DNA Cell Cycle Analysis
Treated and untreated cells were prepared as di-
rected by the NuCycle Dapi Kit (Exalpha Biologicals,
Maynard, MA, USA) and analyzed on a Beckman
Coulter FC 500 cytometer.
Cytokine Analysis
Supernatants from keratinocytes cocultured in the
presence of CD81 T cells, CD41 T cells, or in the ab-
sence of T cells (negative control) were analyzed for the
following cytokines: chemokine ligand 5 (CXCL5),
CXCL11, thrombopoietin (Tpo), tumor necrosis
factor-alpha (TNF-a), G-CSF, epidermal growth fac-tor (EGF), hepatocyte growth factor (HGF),
interferon-inducible cytokine-10 (IP-10), interleukin
1 receptor antagonist (IL-1RA), IL-2, IL-4, IL-6, IL-
8, vascular endothelial growth factor (VEGF), eotaxin,
CD40 ligand (CD40L), leptin, chemokine ligand
5 (RANTES), macrophage inflammatory protein-1
alpha (MIP-1a), and MIP-1b. Measurement of all
cytokines was performed simultaneously by an
immunobead-based multiplex assay (Luminex) accord-
ing to the manufacturer’s instructions. Panels of
capture antibody-coated beads and labeled detection
antibodies were acquired from R&D Systems, Inc.
(Minneapolis, MN, USA).
qPCR for Measurement of Telomere Length
Telomere length of pretreatment peripheral blood
leukocytes was assessed by quantitative polymerase
chain reaction (qPCR) as previously described [12,13].
Total leukocytes were separated by ammonium-based
lysis of red blood cells and DNA was extracted using
the DNeasy Blood kit (Qiagen, Chatsworth, CA,
USA). PCRs were performed in a 7500 Real-Time
PCR System (Applied Biosystems, Foster City, CA,
USA). Each sample’s telomere length (x) was based on
the telomere to single copy gene ratio (T/S ratio) and
on the calculation of the DCt [Ct
(telomeres)/Ct
(single
gene)]. Telomere length was expressed as relative T/S
ratio, which was normalized to the average T/S ratio
of the reference sample [22(DCtx 2 DCtr)5 22DDCt].
P53 Sequencing of Keratinocytes
Screening for TP53 mutations in patients was car-
ried out using direct sequencing in both directions.
PCR primers were designed to amplify exons 5, 6, 7,
8, and 9 of the TP53 gene (ENSG00000141510)
from genomic DNA as 3 separate amplicons. The
primer sequences are available on request. The PCR
products were analyzed using 3730xl DNA analyzer
(Applied Biosystems).RESULTS
Unmanipulated, uncultured buccal mucosal cells
from sites of GVHD show significant numbers of
tetraploid cells.
To determine if chromosomal abnormalities could
be detected in areas of the oral mucosa affected by
GVHD, we obtained buccal mucosal cells from pa-
tients with and without GVHD and performed FISH
using centromeric probes for X/Y. Cells were placed
directly on a slide, fixed, and then stained with
a FISH X/Y probe. The X/Y probe was chosen for
our transplant patient experiments to distinguish
tetraploid cells from fusion cells (in patients with
sex-discordant transplants (XY/XY or XX/XX) from
fusion cells (XY/XX)). When FISH was performed
Table 1. Karyotype Analysis of Buccal Mucosal Cells
Patient GVHD
Donor Sex
Discordant
Time from
Transplant
Transplant
Regimen
% Tetraploid
Area of GVHD
11 Chronic systemic No 18 months Flu/Cy 23/50 (46%)
12 Acute skin IV Yes 5 months Flu/Cy 5/25 (20%)
13 Chronic limited No 20 months Flu/Cy 5/20 (25%)
14 Chronic limited Yes 38 months Flu/Cy 1/5 (20%)
16 Acute skin I Yes 2.5 months Flu/Cy 2/20 (10%)
17 Acute skin 1 Yes 4 months Flu/Cy 3/7 (8%)
18 Chronic limited No 4 months Flu/Cy 6/30 (20%)
19 Chronic limited No 1.3 months Flu/Cy 3/25 (12%)
20 None No 6 months Flu/Cy 0/72 (0%)
21 None No 2 months Flu/Cy 0/21 (0%)
22 None No 22 months Flu/Cy 0/3 (0%)
23 None No 2.6 months Flu/Cy 0/37 (0%)
24 None No 36 months Flu/Cy 0/11 (0%)
25 None No 12 months Flu/Cy 0/12 (0%)
Normal (N 5 10) — — — — 0
GVHD indicates graft-versus-host disease; Flu/Cy, fludarabine/cyclophosphamide.
Buccal mucosal smears were obtained from 8 patients from areas of GVHD and 6 patients from uninvolved areas of the buccal mucosa. Keratinocytes
from GVHD sites forced into repeated cell division by multiple in vitro passaging show even more pronounced tetraploidy than unmanipulated
keratinocytes.
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from 9 patients at sites of oral GVHD, all demon-
strated small numbers of tetraploid cells. None of the
6 BMT patients without a recent history of GVHD
or the 10 healthy controls (ranging in age from 20 to
67 years) showed tetraploidy (Table 1). None of the
4 patients from the GVHD cohort who had sex-
discordant transplants demonstrated XX/XY fusion
cells. Punch biopsies were obtained from individuals
with biopsy-proven GVHD, fixed, embedded in paraf-
fin, and prepared for FISH as previously described
[35]. It has been shown that tissue repair and active
mitosis occur in areas recovering from GVHD. To
determine if repeated cell divisions predispose toward
tetraploidy or aneuploidy, we studied keratinocytes
isolated from biopsies of patients at sites of GVHDTable 2. Karyotype Analysis of Biopsies of Skin in GVHD Patient S
Patient No. Age Dx Conditioning Years after Tra
1 30 AML TBI/Cy 3
2 36 CML TBI/Cy 1
3 21 AML TBI/Cy 2
4 52 CLL TBI/Cy 3
5 37 NHL Flu/Cy 1
6 34 CML Flu/Cy 2
7 42 MDS TBI/Cy 7
8 25 PNH Flu/Cy 0.6
9 46 CML TBI/Cy 6
Normal (N 5 20) — — — —
GVHD indicates graft-versus-host disease; Flu/Cy, fludarabine/cyclophospham
drome; NHL, non-Hodgkin’s leukemia; CLL, chronic lymphocytic leukemia; AM
binuria; TBI/Cy, total body irradiation and cyclophosphamide.
Keratinocytes obtained from skin biopsies of patients with a history of cutaneou
performed using probes for chromosomes X and Y. The last column represent
cent tetraploidy prior to expansion is based on counts done on paraffin-sections
from normals ranged from 0% to 3%, with a median of 2% following scoring o
*Percentages were based on cell counts of 300.and from normal foreskins. Keratinocytes obtained
from areas of GVHD in patients with sex-discordant
transplants were cultured in epithelial growth factor
media for 2 weeks (the media does not support growth
of hematopoietic cells or fibroblasts), passaged 2 times
in 75 cm2 flasks, and subjected to FISH. Tetraploidy
was observed in many of the cultures (N 5 9; mean 5
45%) (Table 2). There was no evidence of fusion cells
in the 4 patients who received sex-discordant trans-
plants stained with X/Y probe (Table 2; patients 6, 7,
8, and 9). When skin biopsies obtained from patients
with GVHD and the healthy keratinocytes were
expanded, tetraploidy was even more pronounced in
patient samples (Table 2). Simple expansion of kerati-
nocytes derived from normal foreskins did not result in
significant tetraploidy or aneuploidy.kin Keratinocytes Following Expansion
nsplant GVHD GVHD on bx
% Tetraploidy*
Before
Expansion
Following
Expansion
I No 1 15
II No 5 23
II Yes 12 98
IV Yes 3 43
I No 4 12
III No 13 67
I No 2 16
II Yes 5 85
II No 1 10
— — 0 1-3
ide; CML, chronic myelogenous leukemia; MDS, myelodysplastic syn-
L, acute myelogenous leukemia; PNH, paroxysmal nocturnal hemoglo-
s GVHDwere expanded through two passages in 75 cm2 flasks and FISH
s the tetraploidy observed prior to and following expansion of cells. Per-
stainedwith X/Y probe. Tetraploidy in expanded keratinocytes obtained
f 300 cells.
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Aneuploidy after Coculture with Peripheral
Blood Mononuclear Cells (PBMCs)
To develop a model for GVHD in which individ-
ual and potentially inciting factors could be controlled,
we examined the effect of HLA-mismatched alloge-
neic lymphocytes on the development of ploidy in
keratinocytes in vitro. Keratinocytes derived from
foreskins, were cultured with allogeneic lymphocytes
for 2 days, after which the nonadherent lymphocytes
were removed. We expanded the remaining keratino-
cytes before performing FISH to select for the live rep-
licating cells that had survived the inflammatory insult.
Chromosomes 7, 8, 11, and 17 were examined because
these are frequently abnormal in SCC [33]. However,
when we examined healthy keratinocyte cultures with
allogeneic PBMCs to mimic inflammation and cellular
injury at sites of GVHD, we saw an increase in tetra-
ploid cell numbers after 2 weeks of culture and 2Figure 1. Coculture of keratinocytes from healthy foreskins with allogeneic m
were cocultured with foreskin, keratinocytes for tetraploid cells could be obser
example of a FISH assay utilizing the X/Y probe is seen (left). Arrows point to
content as measured by flow cytometric methods (right). (B) Keratinocytes coc
7 and 8. Samples cultured with lymphocytes had significantly more tetraploidy
Tetraploidy appeared by day 3 of culture; aneuploidy was not seen until day 1passages (example in Figure 1A; left panel). Tetra-
ploidy could also be visualized when cell nuclei were
stained and analyzed by flow cytometry (example
seen in Figure 1A; right panel). Aneuploidy for either
chromosome 7 or 8 developed after 10 days of culture,
whereas tetraploidy could be observed as early as 3
days (Figure 1B). Untreated keratinocytes demon-
strated only rare tetraploid cells after expansion in
media (Table 1 N 5 20).
CD81 Cells Produce More Ploidy Than CD41
Lymphocytes
To assess whether normal CD4 or CD8 cells were
responsible for the changes observed, we separated
CD4 and CD8 cells by a magnetic column and cul-
tured each population with keratinocytes obtained
from foreskins. Confluent keratinocytes were cultured
with 50,000 CD41 or CD81 cells. As a control, one
aliquot of 100,000 unseparated peripheral bloodismatched lymphocytes. (A) When mismatched allogeneic lymphocytes
ved in keratinocyte cultures cocultured with allogeneic lymphocytes. An
tetraploid cells. Tetraploid cells are also distinguishable based on DNA
ultured with allogeneic were stained with FISH probes for chromosomes
and aneuploidy than samples expanded in the absence of lymphocytes.
0.
Figure 2. Coculture of keratinocytes with CD81 cells compared to CD41 lymphocytes. (A) Samples of PBLs from healthy donors were separated into
CD81 cells and CD41 cells using magnetic columns and these were cultured with keratinocytes. Keratinocytes treated with allogeneic CD81 cells
developed the most tetraploidy and aneuploidy; cyclosporine blocked the effect of CD41 and CD81 cells. (B) Following culture of keratinocytes
with purified CD4 and CD8 cells, media was centrifuged to remove the cells and debris. Samples were then tested for cytokines using an immune
bead-based multiplex assay (Luminex). CD8 cells produced significantly more inflammatory cytokines than CD4 cells following coculture with kerati-
nocytes. Control samples consisted of those keratinocytes cultured for an equal time but without lymphocytes. The fold change compared to controls is
graphed for each cytokine.
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(400 ng/mL) before adding the lymphocytes to the
flask to block lymphocyte proliferation and activation.
Keratinocytes were passaged three times following ad-
dition of lymphocytes and harvested two weeks later.
CD4 cells were less effective in generation of aneu-
ploid and tetraploid cells compared to CD8 cells. Ad-
dition of cyclosporine prevented these chromosomal
changes (Figure 2A). Cultures with CD8 cells pro-
duced more inflammatory cytokines than those with
CD4 cells (Figure 2B).
Inflammation Produced In Vitro by Mismatched
Allogeneic Lymphocytes Decreases
Keratinocytes Telomere Length
Inflammation and cell death accompanyingGVHD
results in significant cell mitosis and repair [37]. To
determine if an inflammatory insult was associated
with decreases in telomere length, we examined the
effect of culturing with unseparated PBLs, purified
CD41 T cells, or CD81 T cells on keratinocyte telo-
mere length. Telomere length was shortened by the
addition of lymphocytes, most significantly after expo-
sure to CD81 cells (Figure 3).
Loss of P53 in Keratinocytes Results from
Deletion of Chromosome 17
To assess whether loss of TP53 could account for
the frequency of tetraploidy and aneuploidy observed
in keratinocyte culture, we stained with a locus-
specific probe (LSP) to p53 and a CEP probe to chro-
mosome 11. When tetraploid and aneuploid cells
were compared with diploid cells, TP53 gain or losswas significantly greater in aneuploid cells (P\ .0001)
(Figure 4). To determine if TP53 loss resulted from
loss of only TP53 or of the entire chromosome 17
(where TP53 resides), we stained cells with an LSP to
TP53 and a CEP probe to 17. These experiments
indicated that the loss of TP53 was the result of the de-
letion of chromosome 17 in the majority of cases (data
not shown) (P\ .0001; Fisher’s exact test).Keratinocytes Exposed to Lymphocytes
Demonstrate No p53 Mutation
To determine if keratinocytes exposed to lympho-
cytes developed mutations in p53, we sequenced the
p53 gene. We found no mutations in either the un-
treated or treated keratinocytes.DISCUSSION
In this study, we observed tetraploid cells in unma-
nipulated buccal mucosal smears obtained from sites of
GVHD. Even greater numbers of polyploid cells were
observed following proliferation of these keratinocytes,
suggesting that repeated cell division played a role in
alteration of chromosome number. Keratinocytes
exposed to allogeneic lymphocytes exhibited some of
the chromosomal abnormalities frequently found in pa-
tients with SCC [27]: aneuploidy for chromosomes 8, 7,
17, and 11, and tetraploidy.We observed loss of p53 in
many of the anueploid cells—a factor that may be re-
sponsible for their continued growth and survival.
Telomere length decreased with keratinocyte expan-
sion, but this decrease was more substantial in
Figure 3. Telomere lengths in keratinocytes cultured with lymphocytes. Left panel: keratinocytes were cultured with PBLs as described in Methods and
Materials and then passaged two times over the course of 17 days. Telomere length was then measured. PBLs caused a decrease in keratinocyte telo-
mere, which was most prominent immediately following cocultivation with lymphocytes. Right panel: keratinocytes were cultured with 30,000 purified
CD41, CD81, and a mixture of similar numbers of CD4 and CD8 cells (ie, 60,000 total lymphocytes), which were preincubated with cyclosporine.
CD81 cells showed the most dramatic change in telomere length.
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notably CD8 cells.
In our experiments, loss of TP53 in most cases
appeared to be related to the deletion of chromosome
17- a frequent finding in SCC [27]- rather than to amu-
tation. Others have observed this nonrandom deletion
of chromosome 17 in cells aneuploid for other chromo-
somes [38]. TP53 triggers apoptosis in aneuploid and
tetraploid cells, and haploinsufficiency is associated
with survival of aneuploid cells [39]. Tetraploidy has
been observed in many premalignant states and may
give rise to aneuploid cells [38]. In one proposed model
of tumorigenesis in ulcerative colitis (UC) [26], nitric
oxide(NO)-induced cell cycle arrest leads to transient
tetraploidy and DNA repair. Reactive oxygen species
repeatedly exposing TP53 to oxidative stress may resultFigure 4. Loss of TP53 gene following coculture with keratinocytes.
An aliquot of lymphocyte-treated keratinocytes was probed with locus
specific p53 signal. Cells were probed with CEP 11 and LSP p53. When
this was analyzed statistically using the Mann-Whitney test, an excess
number of aneuploid and tetraploid cells showed either a gain or loss
of p53 (P\.001).inmutation or loss of heterozygosity of this gene.These
events may result in loss of thisTP53s checkpoint func-
tion and a greater proclivity for malignant transforma-
tion. In the TP53 null mouse, tetraploid cells continue
to divide but are genomically unstable, acquiring
many new translocations or undergoing multipolar mi-
tosis because of duplication of the spindle apparatus,
which results in aneuploidy [40].
P53 protein also plays an important role in elimi-
nating cells with telomere dysfunction by triggering
senescence or apoptosis in cells with shortened telo-
meres [41]. Functional loss or gain of TP53 is associ-
ated with continued telomere erosion and subsequent
formation of dicentric chromosomes resulting from
telomereic fusions [42]. Normal cells, adjacent to
SCC, reportedly have shortened telomeres, suggesting
that reduction of telomere length could be related to
malignant transformation [43]. Inflammatory diseases
with a proclivity for malignant transformation such
as Barrett’s esophagitis [11], ulcerative colitis [44],
and hepatitis [45,46], all show substantial decreases in
telomere length. Telomere shortening is associated
with aneuploidy both in human cancer as well as in
the mouse model [47,48]. End-to-end fusion of telo-
meres with unequal segregation of chromosomes has
been observed in the telomerase-deficient mouse
and is presumed to be the mechanism for aneuploidy
in this circumstance. Epithelial tissue has minimal
telomerase activity, so that factors that increase cell
turnover would be expected to give rise to more pro-
nounced telomere shortening [49].
These findings suggest that inflammation alone in
the absence of immunosuppression may give rise to
tetraploid and aneuploid keratinocytes as well as hap-
loinsufficincy of p53. These events may lead to geno-
mic instability, resulting in malignant transformation
1672 Biol Blood Marrow Transplant 16:1665-1673, 2010E. M. Sloand et al.[50]. This in vitro system may provide a model of
GVHD with inflammation resulting in DNA damage,
loss of TP53, and shortened telomere length—all of
which may be steps in the development of SCC.ACKNOWLEDGMENTS
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